OUR EXPERT NETWORK

• The Missing Partners In microRNA Silencing: What QKI Reveals About RNA Regulatory Complexity

  New research suggests microRNA silencing depends on RNA-binding protein partners like QKI, revealing a more complex regulatory network shaping gene expression.

• The Hidden Bottleneck In Advanced Therapies Isn't Science… It's Translational Friction

  Scientific breakthroughs may spark innovation, but operational excellence ultimately determines which advanced therapies reach patients.

• RNA Therapeutics: Why CMC Strategy Will Define The Next Decade

  As RNA matures into an industrial platform, long-term success will depend less on discovery and more on scalable CMC systems, integration, and execution.

• Rethinking The Oligonucleotide Backbone: Why RNA Therapeutics May Need A New Molecular Design Framework

  New backbone chemistries could unlock greater control over delivery, specificity, and safety, expanding the molecular design space for RNA medicines.

• RNA Platforms: What Transfers And What Breaks

  A practical framework for distinguishing reusable RNA platform knowledge from biology-specific unknowns as therapeutics expand into new tissues and indications.